397 related articles for article (PubMed ID: 19946324)
1. Sevelamer and the bone-vascular axis in chronic kidney disease: bone turnover, inflammation, and calcification regulation.
Brandenburg VM; Jahnen-Dechent W; Ketteler M
Kidney Int Suppl; 2009 Dec; (114):S26-33. PubMed ID: 19946324
[TBL] [Abstract][Full Text] [Related]
2. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
[TBL] [Abstract][Full Text] [Related]
3. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
[TBL] [Abstract][Full Text] [Related]
4. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.
Rastogi A
Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):322-42. PubMed ID: 24327730
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
Koizumi M; Fukagawa M
Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
[TBL] [Abstract][Full Text] [Related]
6. Emerging effects of sevelamer in chronic kidney disease.
Ikee R; Tsunoda M; Sasaki N; Sato N; Hashimoto N
Kidney Blood Press Res; 2013; 37(1):24-32. PubMed ID: 23486088
[TBL] [Abstract][Full Text] [Related]
7. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Sprague SM
Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
Brunner-Ziegler S; Fröschl B; Hiebinger C; Zsifkovits J
Ann Nutr Metab; 2011 Oct; 58(4):315-9. PubMed ID: 21986491
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
Mason MA; Shepler BM
Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
[TBL] [Abstract][Full Text] [Related]
10. Hyperphosphataemia: treatment options.
Malberti F
Drugs; 2013 May; 73(7):673-88. PubMed ID: 23625273
[TBL] [Abstract][Full Text] [Related]
11. Emerging drugs for hyperphosphatemia.
Bellinghieri G; Santoro D; Savica V
Expert Opin Emerg Drugs; 2007 Sep; 12(3):355-65. PubMed ID: 17874966
[TBL] [Abstract][Full Text] [Related]
12. [Management of hyperphosphatemia ; phosphate-binder].
Yokoyama K
Clin Calcium; 2009 Feb; 19(2):205-12. PubMed ID: 19182360
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival data.
Frazão JM; Adragão T
Kidney Int Suppl; 2008 Dec; (111):S38-43. PubMed ID: 19034324
[TBL] [Abstract][Full Text] [Related]
14. Phosphate binders in CKD: chalking out the differences.
Rees L; Shroff RC
Pediatr Nephrol; 2010 Mar; 25(3):385-94. PubMed ID: 19898877
[TBL] [Abstract][Full Text] [Related]
15. [Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].
Malberti F
G Ital Nefrol; 2010; 27 Suppl 52():S47-54. PubMed ID: 21132662
[TBL] [Abstract][Full Text] [Related]
16. Ten-year experience with sevelamer and calcium salts as phosphate binders.
Raggi P; Vukicevic S; Moysés RM; Wesseling K; Spiegel DM
Clin J Am Soc Nephrol; 2010 Jan; 5 Suppl 1():S31-40. PubMed ID: 20089501
[TBL] [Abstract][Full Text] [Related]
17. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects.
Frazão JM; Adragão T
Nephron Clin Pract; 2012; 120(2):c108-19. PubMed ID: 22555359
[TBL] [Abstract][Full Text] [Related]
18. Clinical consequences and novel therapy of hyperphosphatemia: Lanthanum carbonate for dialysis patients.
Cozzolino M; Brancaccio D
Recent Pat Cardiovasc Drug Discov; 2007 Jan; 2(1):29-34. PubMed ID: 18221100
[TBL] [Abstract][Full Text] [Related]
19. A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
St. Peter WL; Wazny LD; Weinhandl E; Cardone KE; Hudson JQ
Drugs; 2017 Jul; 77(11):1155-1186. PubMed ID: 28584909
[TBL] [Abstract][Full Text] [Related]
20. Nonphosphate-binding effects of sevelamer--are they of clinical relevance?
Marangon N; Lindholm B; Stenvinkel P
Semin Dial; 2008; 21(5):385-9. PubMed ID: 18573137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]